Information  X 
Enter a valid email address

Centrica PLC (CNA)

  Print      Mail a friend       Annual reports

Thursday 16 May, 2019

Centrica PLC

Scrip Reference Share Price

RNS Number : 2998Z
Centrica PLC
16 May 2019
 

16 May 2019

Centrica plc ('the Company')

 

Scrip Reference Share Price

 

The Company offers shareholders the opportunity to receive ordinary shares of 614/81 pence each in the Company ('Shares'), ranking equally with existing issued ordinary shares, in place of cash dividends by participating in the Company's Scrip Dividend Programme ('the Programme').

 

On 21 February 2019, the Company announced a final dividend for the year ending 31 December 2018 of 8.40 pence per Share payable on 27 June 2019 to shareholders on the register at close of business on 10 May 2019 (the 'Final Dividend'). The scrip reference share price for those who are, or who will elect to become, participants in the Programme in respect of the Final Dividend is 94.44 pence.

 

The scrip reference share price is the average of the closing middle market quotation for Shares, derived from the London Stock Exchange Daily Official List, for the five consecutive days from 9 May 2019 to 15 May 2019 (inclusive).

 

The deadline for application under the Programme in respect of the Final Dividend is 4:30pm (London time) on 6 June 2019.

 

Programme terms and conditions and mandate forms are available from centrica.com/dividends.

 

 

ENDS

 

Adam Westley

Head of Secretariat, Centrica plc

01753 494000

 

 

Centrica plc is listed on the London Stock Exchange (CNA)
Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD

Registered in England & Wales number: 3033654
Legal Entity Identifier number: E26EDV109X6EEPBKVH76
ISIN number: GB00B033F229

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DIVEAASKFDLNEFF

a d v e r t i s e m e n t